Contrast media nephropathy: in depth review.
Hussain
N
N
Al Otaibi
T
T
Nampoory
M R N
MR
D000111:Acetylcysteine / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D003287:Contrast Media / Q000633:toxicity*; D003928:Diabetic Nephropathies / Q000150:complications; D004298:Dopamine / Q000627:therapeutic use; D065128:Endothelin Receptor Antagonists; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced* / Q000188:drug therapy; D008353:Mannitol / Q000627:therapeutic use; D051437:Renal Insufficiency / Q000139:chemically induced* / Q000188:drug therapy; D012307:Risk Factors
D002121:Calcium Channel Blockers; D003287:Contrast Media; D065128:Endothelin Receptor Antagonists; D008353:Mannitol; D004298:Dopamine; D000111:Acetylcysteine